UMMS Clinical and Educational Conflict of Interest Committee (CECOIC)

 

Introduction

Countless examples exist to support the value of appropriate financial relationships between “Industry” (collectively the pharmaceutical, medical device, medical equipment, medical supplier, medical services, and biotechnology industries) and academic medical centers (AMCs)--research entities and their employees.

Development of new, beneficial, and sometimes life-saving drugs, devices, and tests depends on those relationships, many of which exist in our medical school. Retaining them and promoting new ones are important to our mission as a school as long as they can serve the best interests of our patients. It is important to note that such relationships are always connected to a deliverable—and academic—goal. In some of these research-related arrangements, faculty and staff may receive payment for their work directly from industry or may receive compensation such as stock options, royalties, or other opportunities for personal gain from the deliverable involved in the relationship with industry. It is understood that the aforementioned interactions in and of themselves involve conflict of interest on the part of medical school faculty and staff. Those individuals may stand to gain financially from the industry relationship. The reward may be to the individual or may come through family or a financial entity they or their family controls, such as a foundation. Because these research-related conflicts of interest have inherent bias connected with them, they must be managed appropriately. The structure for doing so has been established in the School and is delegated by the Dean to the Conflict of Interest Board.

Besides the research-related interactions with industry mentioned above, there are other relationships—clinically-and/or educationally-related financial interests—
between faculty and staff and industry that fall within the purview of this Committee.

The overarching principle in developing the Committee's recommendations will be that its recommendations serve the best interests of our patients and the integrity and reputation of our institution and its faculty and staff.

Click here to read the full report of the Conflict of Interest Group.

Note: The Medical School Conflict of Interest Board (MEDCOI) handles COI issues related to research, intellectual property, and technology transfer as well conflict of commitment.

Committee Roster


Committee Charge

The Clinical and Educational COI Committee will serve the Medical School in developing policies governing relationships between UMMS faculty, staff, trainees, students and biomedical industries in clinical and educational realms.

  1.  The policies developed will require advisory review by the UMMS COI Board (MEDCOI), followed by endorsement by the Dean’s Advisory Council – Chairs, prior to being submitted to the UMMS Executive Committee for review and decision regarding final approval.

  2. The Committee will periodically reassess existent policies in light of evolving relationships between the academic health center and biomedical industries.

  3. The Committee will serve as a resource for faculty, staff, trainees, and students in evaluating existent and potential relationships with biomedical industries and in determining whether they are allowable within the provisions of established policies.

  4. The chairperson and voting members of the Committee will be appointed by the Dean and serve at the pleasure of the Dean.

  5. The Committee will meet a minimum of six times per year.

Charge approved by the UMMS Executive committee November 11, 2010
Minor revision January 25, 2011

Updated 7/19/12